A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

• Drug: PF-06743649
  
  40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
• Drug: Placebo
  
  Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
• Drug: PF-06743649
  
  To be decided dose, tablet once daily dosing for 14 days
• Drug: Placebo
  
  Placebo tablet once daily dosing for 14 days
• Drug: PF-06743649
  
  To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
• Drug: PF-06743649
  
  To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
• Drug: Placebo
  
  Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
• Drug: PF-06743649
  
  Tablet, to be decided dose, once daily, 14 days
• Drug: Placebo
  
  Tablet, once daily, 14 days

• Experimental: Cohort 1-PF-06743649 or placebo
  
  Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3
  Interventions:
  

  • Drug: PF-06743649
  • Drug: Placebo
• Experimental: Cohort 2-PF-06743649 or placebo
  
  Interventions:
  

  • Drug: PF-06743649
  • Drug: Placebo
• Experimental: Cohort 3-PF-06743649 or placebo
  
  Interventions:
  

  • Drug: PF-06743649
  • Drug: Placebo
• Experimental: Cohort 4-PF-06743649 or placebo
  
  Interventions:
  

  • Drug: PF-06743649
  • Drug: Placebo
• Experimental: Cohort 5-PF-06743649 or placebo
  
  Interventions:
  

  • Drug: PF-06743649
  • Drug: Placebo

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
• Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Any condition possibly affecting drug absorption (eg, gastrectomy).
• Evidence of gout/hyperuricemia, measured sUA >8 mg/dL at screening.
• Experienced an episode of nephrolithiasis or ureterolithiasis.